Practitioner's Docket No. 48460 (70157)

CHAPTER II

TRANSMITTAL LETTER TO THE UNITED STATES ELECTED OFFICE (EO/US)

(ENTRY INTO U.S. NATIONAL PHASE UNDER CHAPTER II)

PCT/US00/01968	25 January 2000	26 January 1999
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED

PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE THEREOF
TITLE OF INVENTION

Andre ROSOWSKY
APPLICANT(S)

Box PCT
Assistant Commissioner for Patents
Washington D.C. 20231

ATTENTION: EO/US

NOTE: To avoid abandonment of the application, the applicant shall furnish to the USPTO, not later than 20 months from the priority date: (1) a copy of the international application, unless it has been previously communicated by the International Bureau or unless it was originally filed in the USPTO; and (2) the basic national fee (see 37 C.F.R. § 1.492(a)). The 30-month time limit may not be extended. 37 C.F.R. § 1.495.

CERTIFICATION UNDER 37 C.F.R. § 1.10*
(Express Mail label number is mandatory.)
(Express Mail certification is optional.)

I hereby certify that this Transmittal Letter and the papers indicated as being transmitted therewith is being deposited with the United States Postal Service on this date 26 July 2001, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EL835032941US, addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Susan M. Dillon
(type or print name of person mailing paper)

Susan M Dillon
Signature of person mailing paper

WARNING: *Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. § 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.*

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. § 1.10(b).*
*"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.*

WARNING: *Where the items are those which can be submitted to complete the entry of the international application into the national phase are subsequent to 30 months from the priority date the application is still considered to be in the international state and if mailing procedures are utilized to obtain a date the express mail procedure of 37 C.F.R. § 1.10 must be used (since international application papers are not covered by an ordinary certificate of mailing - See 37 C.F.R. § 1.8.*

NOTE: Documents and fees must be clearly identified as a submission to enter the national state under 35 U.S.C. § 371 otherwise the submission will be considered as being made under 35 U.S.C. § 111. 37 C.F.R. § 1.494(f).

I. Applicant herewith submits to the United States Elected Office (EO/US) the following items under 35 U.S.C. § 371:

a. ☒ This express request to immediately begin national examination procedures (35 U.S.C. § 371(f)).

b. ☒ The U.S. National Fee (35 U.S.C. § 371(c)(1)) and other fees (37 C.F.R. § 1.492) as indicated below:

2. Fees

CLAIMS FEE	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
☐*	TOTAL CLAIMS	35 -20=	15.00	× 18.00	$ 270.00
	INDEPENDENT CLAIMS	10 -3=	7	× 80.00	$560.00
	MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ $270.00	$270.00
BASIC FEE**	☒ U.S. PTO WAS INTERNATIONAL PRELIMINARY EXAMINATION AUTHORITY Where an international preliminary examination fee as set forth in § 1.482 has been paid on the international application to the U.S. PTO: ☐ and the international preliminary examination report states that the criteria of novelty, inventive step (non-obviousness) and industrial activity, as defined in PCT Article 33(1) to (4) have been satisfied for all the claims presented in the application entering the national stage (37 CFR 1.492(a)(4)) ..... $98.00 ☒ and the above requirements are not met (37 CFR 1.492(a)(1)) ..... $720.00 ☐ U.S. PTO WAS NOT INTERNATIONAL PRELIMINARY EXAMINATION AUTHORITY Where no international preliminary examination fee as set forth in § 1.482 has been paid to the U.S. PTO, and payment of an international search fee as set forth in § 1.445(a)(2) to the U.S. PTO: ☐ has been paid (37 CFR 1.492(a)(2)) ..... $790.00 ☐ has not been paid (37 CFR 1.492(a)(3)) ..... $1,070.00 ☐ where a search report on the international application has been prepared by the European Patent Office or the Japanese Patent Office (37 CFR 1.492(a)(5)) $930.00				$690.00
	Total of above Calculations				= $1,790.00
SMALL ENTITY	Reduction by 1/2 for filing by small entity, if applicable. Affidavit must be filed also. (note 37 CFR 1.9, 1.27, 1.28)				- $ 895.00
	Subtotal				$ 895.00
	Total National Fee				$ 895.00
	Fee for recording the enclosed assignment document $40.00 (37 CFR 1.21(h)). (See Item 13 below). See attached "ASSIGNMENT COVER SHEET".				
TOTAL	Total Fees enclosed				$ 895.00

*See attached Preliminary Amendment Reducing the Number of Claims.

i. ☒ A check in the amount of 895.00 to cover the above fees is enclosed.

ii. ☐ Please charge Account No. _____ in the amount of $ _____. A duplicate copy of this sheet is enclosed.

***WARNING:** *"To avoid abandonment of the application the applicant shall furnish to the United States Patent and Trademark Office not later than the expiration of 30 months from the priority date: * * * (2) the basic national fee (see § 1.492(a)). The 30-month time limit may not be extended." 37 C.F.R. § 1.495(b).*

WARNING: *If the translation of the international application and/or the oath or declaration have not been submitted by the applicant within thirty (30) months from the priority date, such requirements may be met within a time period set by the Office. 37 C.F.R. § 1.495(b)(2). The payment of the surcharge set forth in § 1.492(e) is required as a condition for accepting the oath or declaration later than thirty (30) months after the priority date. The payment of the processing fee set forth in § 1.492(f) is required for acceptance of an English translation later than thirty (30) months after the priority date. Failure to comply with these requirements will result in abandonment of the application. The provisions of § 1.136 apply to the period which is set. Notice of Jan. 3, 1993, 1147 O.G. 29 to 40.*

3. ☒ A copy of the International application as filed (35 U.S.C. § 371(c)(2)):

NOTE: Section 1.495 (b) was amended to require that the basic national fee and a copy of the international application must be filed with the Office by 30 months from the priority date to avoid abandonment. "The International Bureau normally provides the copy of the international application to the Office in accordance with PCT Article 20. At the same time, the International Bureau notifies applicant of the communication to the Office. In accordance with PCT Rule 47.1, that notice shall be accepted by all designated offices as conclusive evidence that the communication has duly taken place. Thus, if the applicant desires to enter the national stage, the applicant normally need only check to be sure the notice from the International Bureau has been received and then pay the basic national fee by 30 months from the priority date." Notice of Jan. 7, 1993, 1147 O.G. 29 to 40, at 35-36. See item 14c below.

a. ☐ is transmitted herewith.

b. ☒ is not required, as the application was filed with the United States Receiving Office.

c. ☐ has been transmitted

i. ☐ by the International Bureau.
Date of mailing of the application (from form PCT/1B/308): _____.

ii. ☐ by applicant on _____.
Date

4. ☒ A translation of the International application into the English language (35 U.S.C. § 371(c)(2)):

a. ☐ is transmitted herewith.

b. ☒ is not required as the application was filed in English.

c. ☐ was previously transmitted by applicant on _____.
Date

d. ☐ will follow.

5. ☒ Amendments to the claims of the International application under PCT Article 19 (35 U.S.C. § 371(c)(3)):

NOTE: The Notice of January 7, 1993 points out that 37 C.F.R. § 1.495(a) was amended to clarify the existing and continuing practice that PCT Article 19 amendments must be submitted by 30 months from the priority date and this deadline may not be extended. The Notice further advises that: "The failure to do so will not result in loss of the subject matter of the PCT Article 19 amendments. Applicant may submit that subject matter in a preliminary amendment filed under section 1.121. In many cases, filing an amendment under section 1.121 is preferable since grammatical or idiomatic errors may be corrected." 1147 O.G. 29-40, at 36.

a. ☐ are transmitted herewith.

b. ☐ have been transmitted

i. ☐ by the International Bureau.
Date of mailing of the amendment (from form PCT/1B/308): _____.

ii. ☐ by applicant on (date) _____.
Date

c. ☒ have not been transmitted as

i. ☒ applicant chose not to make amendments under PCT Article 19.
Date of mailing of Search Report (from form PCT/ISA/210.): _____.

ii. ☐ the time limit for the submission of amendments has not yet expired. The amendments or a statement that amendments have not been made will be transmitted before the expiration of the time limit under PCT Rule 46.1.

6. ☒ A translation of the amendments to the claims under PCT Article 19 (38 U.S.C. § 371(c)(3)):

a. ☐ is transmitted herewith.

b. ☐ is not required as the amendments were made in the English language.

c. ☒ has not been transmitted for reasons indicated at point 5(c) above.

7. ☒ A copy of the international examination report (PCT/IPEA/409)

☒ is transmitted herewith.

☐ is not required as the application was filed with the United States Receiving Office.

8. ☐ Annex(es) to the international preliminary examination report

a. ☐ is/are transmitted herewith.

b. ☐ is/are not required as the application was filed with the United States Receiving Office.

9. ☒ A translation of the annexes to the international preliminary examination report

a. ☐ is transmitted herewith.

b. ☒ is not required as the annexes are in the English language.

10. ☒ An oath or declaration of the inventor (35 U.S.C. § 371(c)(4)) complying with 35 U.S.C. § 115

    a. ☐ was previously submitted by applicant on _____. Date

    b. ☐ is submitted herewith, and such oath or declaration

        i. ☐ is attached to the application.

        ii. ☐ identifies the application and any amendments under PCT Article 19 that were transmitted as stated in points 3(b) or 3(c) and 5(b); and states that they were reviewed by the inventor as required by 37 C.F.R. § 1.70.

        iii. ☒ will follow.

II. Other document(s) or information included:

11. ☒ An International Search Report (PCT/ISA/210) or Declaration under PCT Article 17(2)(a):

    a. ☒ is transmitted herewith.

    b. ☐ has been transmitted by the International Bureau. Date of mailing (from form PCT/IB/308): _____.

    c. ☐ is not required, as the application was searched by the United States International Searching Authority.

    d. ☐ will be transmitted promptly upon request.

    e. ☐ has been submitted by applicant on _____. Date

12. ☒ An Information Disclosure Statement under 37 C.F.R. §§ 1.97 and 1.98:

    a. ☐ is transmitted herewith.

        Also transmitted herewith is/are:

        ☐ Form PTO-1449 (PTO/SB/08A and 08B).

        ☐ Copies of citations listed.

    b. ☒ will be transmitted within THREE MONTHS of the date of submission of requirements under 35 U.S.C. § 371(c).

    c. ☐ was previously submitted by applicant on _____. Date

13. ☐ An assignment document is transmitted herewith for recording.

    A separate ☐ "COVER SHEET FOR ASSIGNMENT (DOCUMENT) ACCOMPANYING NEW PATENT APPLICATION" or ☐ FORM PTO 1595 is also attached.

_____

_____

_____

14. ☒ Additional documents:
    a. ☐ Copy of request (PCT/RO/101)
    b. ☒ International Publication No. WO 00/59884
        i. ☒ Specification, claims and drawing
        ii. ☐ Front page only
    c. ☐ Preliminary amendment (37 C.F.R. § 1.121)
    d. ☒ Other
    Form PCT/IB/304, Form PCT/IB/301, Form PCT/IPEA/408

15. ☒ The above checked items are being transmitted
    a. ☒ before 30 months from any claimed priority date.
    b. ☐ after 30 months.

16. ☐ Certain requirements under 35 U.S.C. § 371 were previously submitted by the applicant on _____, namely:

AUTHORIZATION TO CHARGE ADDITIONAL FEES

WARNING: *Accurately count claims, especially multiple dependant claims, to avoid unexpected high charges if extra claims are authorized.*

NOTE: "A written request may be submitted in an application that is an authorization to treat any concurrent or future reply, requiring a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. An authorization to charge all required fees, fees under § 1.17, or all required extension of time fees will be treated as a constructive petition for an extension of time in any concurrent or future reply requiring a petition for an extension of time under this paragraph for its timely submission. Submission of the fee set forth in § 1.17(a) will also be treated as a constructive petition for an extension of time in any concurrent reply requiring a petition for an extension of time under this paragraph for its timely submission." 37 C.F.R. § 1.136(a)(3).

NOTE: "Amounts of twenty-five dollars or less will not be returned unless specifically requested within a reasonable time, nor will the payer be notified of such amounts; amounts over twenty-five dollars may be returned by check or, if requested, by credit to a deposit account." 37 C.F.R. § 1.26(a).

☒ The Commissioner is hereby authorized to charge the following additional fees that may be required by this paper and during the entire pendency of this application to Account No. 04-1105.

☒ 37 C.F.R. § 1.492(a)(1), (2), (3), and (4) (filing fees)

WARNING: *Because failure to pay the national fee within 30 months without extension (37 CFR § 1.495(b)(2)) results in abandonment of the application, it would be best to always check the above box.*

☒ 37 C.F.R. § 1.492(b), (c) and (d) (presentation of extra claims)

NOTE: Because additional fees for excess or multiple dependent claims not paid on filing or on later presentation must only be paid or these claims cancelled by amendment prior to the expiration of the time period set for response by the PTO in any notice of fee deficiency (37 C.F.R. § 1.492(d)), it might be best not to authorize the PTO to charge additional claim fees, except possible when dealing with amendments after final action.

☒ 37 C.F.R. § 1.17 (application processing fees)

☒ 37 C.F.R. § 1.17(a)(1)–(5) (extension fees pursuant to § 1.136(a).

☐ 37 C.F.R. § 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. § 1.311(b))

NOTE: Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance. 37 C.F.R. § 1.311(b).

NOTE: 37 C.F.R. § 1.28(b) requires "Notification of any change in loss of entitlement to small entity status must be filed in the application . . . prior to paying, or at the time of paying . . . issue fee." From the wording of 37 C.F.R. § 1.28(b): (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change is to another small entity.

☐ 37 C.F.R. § 1.492(e) and (f) (surcharge fees for filing the declaration and/or filing an English translation of an International Application later than 30 months after the priority date).

SIGNATURE OF PRACTITIONER

Reg. No.: 33,860

Peter F. Corless

(type or print name of practitioner)

Tel. No.: (617) 439-4444

Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group

Customer No.:

P.O. Address

EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209

PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE THEREOF

This invention was made with government support under Grant No. RO1A129904 awarded by the National Institutes of Health. The government has certain rights in this invention.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to pharmaceutically active compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for the treatment or prophylaxis of diseases associated with parasitic infection, such as toxoplasmosis, cryptosporidiosis, leischmaniasis and malaria.

2. Background

Parasitic-related diseases are highly prevalent and often difficult to treat. For example, toxoplasmosis, caused by the parasitic protozoan *Toxoplasma gondii*, is a leading cause of morbidity and morality in patients with AIDS as well as in other immunocompromised patients such as persons receiving immunosuppressive cancer chemotherapy. Toxoplasmosis also is suffered by the developing fetus with the potential result of severe neurological damage. The disease is also problematic for livestock and other domesticated animals. For example, toxoplasmosis causes spontaneous abortion in sheep.

Pneumocytis pneumonia, cryptosporidiosis, leischmaniasis and malaria also result from parāsitic infection and can be difficult to treat, particularly in immunocompromised subjects. Pneumocytis pneumonia results from infection by *Pnemocystis carinii*, a fungal parasite which is benign in immunocomponent

individuals but can be life-threatening in patients with AIDS. Cryptosporidiosis results from infection of protozoa of the genus *Cryptosporidium* and, in the case of immunocompromised individuals, the disease can be chronic and life threatening. Leischmaniasis is any of a group of conditions resulting from *Leishmania* infection. Manifestations of leischmaniasis are significantly enhanced in the immunocompromised. Malaria can result from infection of several different parasites: *Plasmodium vivax*, *P. falciparum*, *P. malarie*, and *P. ovale*. See generally *The Merck Manual*, 16th edition.

Current therapies to treat toxoplasmosis and other parasitic infections have included use of trimethoprim and pyrimethamine. See *Merck Index* 8169 and 9840 (12th edition.). However, these agents are often not sufficiently potent to be fully effective when used alone and, consequently, the agents are typically administered in combination with a sulfa drug.

That combination drug therapy, however, has clear shortcomings. Many patients exhibit severe allergic reactions to sulfa drugs, and the therapy must be discontinued prior to effective treatment of the disease.

It thus would be desirable to have new therapies to treat parasitic related diseases, such as toxoplasmosis, cryptosporidiosis, leischmaniasis and malaria.

SUMMARY OF THE INVENTION

I have now found new compounds that exhibit significant anti-parasitic activity and will be useful to treat subjects suffering from or susceptible to various parasitic related disorders and diseases, including but not limited to toxoplasmosis, cryptosporidiosis, leischmaniasis and/or malaria.

More specifically, in a first aspect, compounds of the following Formula I are provided:



I

wherein Ar is optionally substituted carbocyclic aryl or optionally substituted heteroaromatic;

W is a chemical bond, optionally substituted amino (e.g. -NH-), an optionally substituted alkylene group preferably having 1 to about 3 carbons, more preferably 1 or 2 carbon atoms such as $-CH_2-$ or $-CH_2CH_2-$, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms (e.g. $-CH_2NH-$);

X is nitrogen or carbon;

Z represents a chemical bond (i.e. a direct bridge to provide a carbazole), optionally substituted methylene or ethylene (i.e. optionally substituted $-CH_2-$ or $-CH_2CH_2-$), optionally substituted vinyl (i.e. optionally substituted –CH=CH-), optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents hydrogens or other non-linked substituents on each phenyl group (i.e. Z is not a bridge group to thereby provide a diphenylamine);

each R^1 and R^2 independently may be halogen; amino; hydroxy; nitro; azido; optionally substituted alkyl preferably having 1 to about 12 carbon atoms; optionally substituted alkenyl preferably having 2 to about 12 carbon atoms; optionally substituted alkynyl preferably having 2 to about 12 carbon atoms; optionally substituted alkoxy preferably having 1 to about 12 carbon atoms; optionally substituted aminoalkyl preferably having 1 to about 12 carbon atoms; optionally substituted alkanoyl optionally having 1 to about 12 carbon atoms; optionally substituted alkylthio preferably having 1 to about 12 carbon atoms; optionally substituted alkylsulfinyl preferably having 1 to about 12 carbon atoms; optionally substituted alkylsulfonyl preferably having 1 to about 12 carbon atoms; optionally substituted carbocyclic aryl; or optionally substituted heteroaromatic or heteroalicyclic preferably having from 1 to 3 separate or fused rings and with 1 to 3 hetero (N, O or S) atoms;

m and n are each independently an integer of from 0 (where a ring is fully-hydrogen substituted) to 4; and pharmaceutically acceptable salts thereof.

As discussed above, Z in the above Formula I can be non-linked hydrogen or other substituents on each phenyl group, such as compounds of the following Formula IA:



IA

wherein in Formula IA, Ar, X, W, R^1 and R^2 are the same as defined above for Formula I; and m and n are each independently an integer of from 0 (where a ring is fully-hydrogen substituted) to 5; and pharmaceutically acceptable salts thereof.

Preferred compounds of the invention include those of Formula I where W is optionally substituted alkylene, particularly C_{1-3}alkylene, or optionally substituted nitrogen, even more preferably compounds of the following Formula II or IIA:



II



IIA

wherein in Formulae II and IIA, Ar, Z, R^1, R^2, m and n are each the same as defined above for Formula I; and pharmaceutically acceptable salts thereof.

Preferred compounds of the invention also include those where the aryl group (Ar) is a single or fused group, such as compounds of the following Formula III:



III

wherein in Formula III, T, U and V are each independently optionally substituted carbon, or optionally substituted nitrogen;

each R^3 is independently selected from the same group of substituents as identified above for R^1 and R^2; or two R^3 groups on adjacent ring atoms are taken together to form a fused carbocyclic aryl, heteroaromatic, cycloalkyl or heteroalicyclic ring having from 5 to about 7 ring member,

o is an integer of from 0 (where the ring is fully hydrogen substituted) to 5;

W, X, R^1, R^2, m and n are each the same as defined above for Formula I; and pharmaceutically acceptable salts thereof.

Particularly preferred compounds of the invention include those of the following Formulae IV and IVA:





wherein in each of Formulae IV and IVA, U and V are each independently optionally substituted carbon, or optionally substituted nitrogen;

Z, X, W, R^1, R^2, m and n are each the same as defined above for Formula I; and pharmaceutically acceptable salts thereof.

As mentioned above, compounds of the invention (i.e. compounds of Formulae I, IA, II, IIA, III, IV and IVA) are useful for a number of therapeutic applications. In particular, the invention includes methods for treatment and/or

prophylaxis of parasitic related diseases, including diseases or disorders associated with *Toxoplasma gondii*, *Pneumocystis carinii*, *Cryptosporidium* including *Cryptosporidium parvum*, *Leishmania*, *Plasmodium vivax*, *P. falciparum*, *P. malarie*, and/or *P. ovale* infections. Compounds of the invention also will be useful for treatment and/or prophylaxis against tuberculosis, particularly in immunocompromised patients, such as AIDS patients, who may have enhanced susceptibility to tuberculosis. The treatment methods of the invention in general comprise administration of a therapeutically effective amount of a compound of the invention to a patient in need thereof.

Compounds of the invention are especially useful for treatment of a mammal, particularly a primate such as a human, suffering from or susceptible to toxoplasmosis. Compounds of the invention also are useful for treatment of a mammal, particularly a primate such as a human, suffering from or susceptible to other parasite-related diseases and disorders such as cryptosporidiosis, leischmaniasis and malaria.

Compounds of the invention are particularly useful for treatment of subjects that are susceptible to such parasitic related disorders and diseases, i.e. prophylactic treatment. For instance, compounds of the invention may be administered as prophylactic treatment to AIDS patients and patients receiving immunosuppressive cancer treatments, who are particularly susceptible to toxoplasmosis, cryptosporidiosis, leischmaniasis and other parasitic related disorders and diseases. Unless otherwise indicated, references herein to "treatment," "therapy," or the like are inclusive of treating a subject that is suffering from a targetted disease or disorder, as well as prophylactic treatment, i.e. treating a subject that may be susceptible to such a disorder or disease.

Particularly preferred compounds of the invention exhibit inhibition activity in a standard dihydrofolate reductase assay e.g. as disclosed in Example 72 which follows. References herein to a "standard dihydrofolate reductase assay" refer to an assay of the protocol set forth in that Example 72 which follows, and which includes spectrophotometric assay of dihydrofolate redutase without test compound (control)

and then such assay of dihydrofolate redutase in the presence of varying concentrations of test compound.

Without being bound by theory, it is believed compounds of the invention can exhibit potent and selective anti-parasitic activity upon administration to a subject due to the presence of the two fused or unfused phenyl groups (i.e. the phenyl groups that are optionally substituted by R^1 and R^2 in Formula I above). See, for instance, the results set forth in Example 72 which follows. More particularly, it is believed that one of those phenyl groups can interact hydrophobically with lipophilic amino acid residues in the active site of dihydrofolate reductase in both the parasite and host, only the active site of the parasite enzyme is sufficiently spacious to accommodate both phenyl groups of compounds of the invention, thereby providing for selective treatment against the parasite.

The invention also provides pharmaceutical compositions that comprise one or more compounds of the invention and a suitable carrier for the compositions.

Other aspects of the invention are disclosed *infra*.

DETAILED DESCRIPTION OF THE INVENTION

As discussed above, we have now discovered that compounds of the following Formula I, IA, II, IIA, III, IV and IVA (i.e. compounds of the invention) are useful for therapeutic applications, particularly against parasitic-related diseases and disorders.



I



IA



II



IIA



III



IV



IVA

wherein Ar, W, X, Z, R^1, R^2, R^3, T, U, V, m, n and o are as defined above.

Preferred compounds of the invention are amino pyrimidine compounds, particularly 2.4-diaminopyrimidine and condensed 2,4-diaminopyrimidine compounds.

Suitable halogen substituent groups of compounds of Formulae I, IA, II, IIA, III, IV and IVA, as defined above (i.e. compounds of the invention) include F, Cl, Br and I. Alkyl groups of compounds of the invention typically have from 1 to about 12 carbon atoms, more preferably 1 to about 8 carbon atoms, still more preferably 1 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms, or still more preferably 1, 2 or 3 carbon atoms. As used herein, the term alkyl unless otherwise modified refers to both cyclic and noncyclic groups, although of course cyclic groups

will comprise at least three carbon ring members. Preferred alkenyl and alkynyl groups of compounds of the invention have one or more unsaturated linkages and typically from 2 to about 12 carbon atoms, more preferably 2 to about 8 carbon atoms, still more preferably 2 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms. The terms alkenyl and alkynyl as used herein refer to both cyclic and noncyclic groups, although straight or branched noncyclic groups are generally more preferred. Preferred alkoxy groups of compounds of the invention include groups having one or more oxygen linkages and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms. Preferred alkylthio groups of compounds of the invention include those groups having one or more thioether linkages and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylthio groups having 1, 2, 3 or 4 carbon atoms are particularly preferred. Preferred alkylsulfinyl groups of compounds of the invention include those groups having one or more sulfoxide (SO) groups and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylsulfinyl groups having 1, 2, 3 or 4 carbon atoms are particularly preferred. Preferred alkylsulfonyl groups of compounds of the invention include those groups having one or more sulfonyl (SO_2) groups and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylsulfonyl groups having 1, 2, 3 or 4 carbon atoms are particularly preferred. Preferred aminoalkyl groups include those groups having one or more primary, secondary and/or tertiary amine groups, and from 1 to about 12 carbon atoms, more preferably 1 to about 8 carbon atoms, still more preferably 1 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms. Secondary and tertiary amine groups are generally more preferred than primary amine moieties. Suitable heteroaromatic groups of compounds of the invention contain one or more N, O or S atoms and 1-3 separate or fused rings and include, e.g., coumarinyl including 8-coumarinyl, quinolinyl including 8-quinolinyl, pyridyl, pyrazinyl, pyrimidyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, oxidizolyl, triazole, imidazolyl, indolyl, benzofuranyl and benzothiazol. Optionally substituted pteridine is a particularly

preferred Ar group of compounds of Formula I, IA, II, and III (i.e. in Formula III U and V are each nitrogen, and two R^3 groups are taken together to form a pteridine group), particularly pteridine substituted at the 6 position to the W group linkage. Suitable heteroalicyclic groups of compounds of the invention contain one or more N, O or S atoms and 1-3 separate or fused rings and include, e.g., tetrahydrofuranyl, thienyl, tetrahydropyranyl, piperidinyl, morpholino and pyrrolindinyl groups. Suitable carbocyclic aryl groups of compounds of the invention include single and multiple ring compounds, including multiple ring compounds that contain separate and/or fused aryl groups. Typical carbocyclic aryl groups of compounds of the invention contain 1 to 3 separate or fused rings and from 6 to about 18 carbon ring atoms. Specifically preferred carbocyclic aryl groups include phenyl; naphthyl including 1-naphthyl and 2-naphthyl; biphenyl; phenanthryl; anthracyl; and acenaphthyl.

Suitable aralkyl groups of compounds of the invention include single and multiple ring compounds, including multiple ring compounds that contain separate and/or fused aryl groups. Typical aralkyl groups contain 1 to 3 separate or fused rings and from 6 to about 18 carbon ring atoms. Preferred aralkyl groups include benzyl and methylenenaphthyl (-CH_2-naphthyl), and other carbocyclic aralkyl groups, as discussed above.

As discussed above, W groups of Formulae I, IA, III, IV and IVA suitably are optionally substituted C_{1-3} alkylene, more preferably CH_2 or CH_2CH_2, or an optionally substituted amino such as –NH-, -NH(CH_3)-, etc., or optionally substituted aminoalkylene such as -CH_2NH-, -$NHCH_2$-, -CH_2CH_2NH-, -$NHCH_2CH_2$-, or -CH_2NHCH_2-. carbon atoms, still more preferably 1, 2 or 3 carbon atoms.

Particularly preferred Z groups of Formula I, II, IIA, III, IV and IVA include –CH_2-, -CH_2CH_2-, -CH=CH-, NH, O and S, with -CH=CH- being particularly preferred.

Specifically preferred compounds of the invention include the following:

N-(2,4-diaminopteridin-6-yl)methyl-N,N-diphenylamine;

2,4-diamino-6-(carbazol-5-yl)methylpteridine;

2,4-diamino-6-(9,10-dihydroacridin-9-yl)methylpteridine;

N-[(2,4-diaminopteridin-6-yl)methyl]phenoxazine;

N-[(2,4-diaminopteridin-6-yl)methyl]phenothiazine;

N-[(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;

N-[(2,4-diaminopteridin-6-yl)methyl]dibenz[*b,f*]azepine;

N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]-N,N-diphenylamine;

N-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]-N,N-diphenylamine;

N-[(2,4-diaminoquinazolin-6-yl)methyl]-N,N-diphenylamine;

N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine;

N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine;

N-[(2,4-diaminopyrimidin-6-yl)methyl-N,N-diphenylamine;

N-[(2,4-diaminopteridin-6-yl)methyl]carbazole;

N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]carbazole;

N-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]carbazole;

N-[(2,4-diaminoquinazolin-6-yl)methyl]carbazole;

N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]carbazole;

N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]carbazole;

N-[(2,4-diaminopyrimidin-6-yl)methyl]carbazole;

N-[(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydroacridine;

N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]-9,10-dihydroacridine;

N-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]-9,10-dihydroacridine;

N-[(2,4-diaminoquinazolin-6-yl)methyl]-9,10-dihydroacridine;

N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydroacridine;

N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydroacridine;

N-[(2,4-diaminopyrimidin-6-yl)methyl]-9,10-dihydroacridine;

N-[(2,4-diaminopteridin-6-yl)methyl]phenoxazine;

9-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]phenoxazine;

9-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]phenoxazine;

9-[(2,4-diaminoquinazolin-6-yl)methyl]phenoxazine;

9-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]phenoxazine;

9-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]phenoxazine;

9-[(2,4-diaminopyrimidin-6-yl)methyl]phenoxazine;

N-[(2,4-diaminopteridin-6-yl)methyl]phenothiazine;

9-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]phenothiazine;

9-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]phenothiazine;

9-[(2,4-diaminoquinazolin-6-yl)methyl]phenothiazine;

9-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl]phenothiazine;

9-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]phenothiazine;

9-[(2,4-diaminopyrimidin-5-yl)methyl]phenothiazine;

N-[(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[*b*,*f*]azepine;

N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]-9,10-dihydrodibenz[*b*,*f*]azepine;

N-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]-9,10-dihydrodibenz[*b*,*f*]azepine;

9-[(2,4-diaminoquinazolin-6-yl)methyl]-9,10-dihydrodibenz[*b*,*f*]azepine;

9-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydrodibenz[*b*,*f*]azepine;

9-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydrodibenz[*b*,*f*]azepine;

9-[(2,4-diaminopyrimidin-5-yl)methyl]-9,10-dihydrodibenz[*b*,*f*]azepine;

N-[(2,4-diaminopteridin-6-yl)methyl]dibenz[*b,f*]azepine;

9-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]dibenz[*b,f*]azepine;

9-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]dibenz[*b,f*]azepine;

9-[(2,4-diaminoquinazolin-6-yl) methyl]dibenz[*b,f*]azepine;

9-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]dibenz[*b,f*]azepine;

9-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]dibenz[*b,f*]azepine;

9-[(2,4-diaminopyrimidin-6-yl)methyl]dibenz[*b,f*]azepine;

N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)benzhydrylamine;

N-(2,4-diaminoquinazolin-6-yl)benzhydrylamine;

N-[(2,4-diaminopyrimidin-5-yl)methyl]benzhydrylamine;

N-[(2,4-diaminopyrimidin-5-yl)ethyl]benzhydrylamine;

9-[N-(2,4-diaminoquinazolin-6-yl)amino]fluorene;

9-[N-(2,4-diaminoquinazolin-5-yl)methylamino]fluorene;

9-[N-[2-(2,4-diaminoquinazolin-5-yl)ethyl]amino]fluorene;

5-[N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]-5*H*-10,11-dihydro-dibenzo[*a,d*]cycloheptene;

5-[N-(2,4-diaminoquinazolin-6-yl)amino]-5*H*-10,11-dihydrodibenzo[*a,d*]cycloheptene;

5-[N-(2,4-diaminopyrimidin-5-yl)methylamino]-5*H*-10,11-dihydrodibenzo [*a,d*]cycloheptene;

5-[N-[2-(2,4-diaminopyrimidin-5-yl)ethyl]amino]-5*H*-10,11-dihydrodibenzo [*a,d*]cycloheptene;

5-[N-(2,4-diaminopyrimidin-[2,3-*d*]pyrimidin-6-yl)amino]-5*H*-dibenzo [*a,d*]cycloheptene;

5-[N-(2,4-diaminoquinazolin-6-yl)amino]-5*H*-dibenzo [*a,d*]cycloheptene;

5-[N-(2,4-diaminopyrimidin-5-yl)methylamino]-5*H*-dibenzo[*a*,*d*]cycloheptene; and 5-[N-[2-(2,4-diaminopyrimidin-5-yl)ethyl]amino]-5*H*-dibenzo[*a*,*d*]cycloheptene; and pharmaceutically acceptable salts thereof.

Compounds of the invention may be readily prepared. For instance, a suitable aryl compound (Ar group precursor) linked to W group precursor that has a reactive carbon (e.g. a carbon substituted with a suitable leaving group such as halogen e.g. Br or I) can be reacted in the presence of a hydride or other suitable base with a fused ring compound, or a diphenyl amine to provide compounds of the invention. Thus, for example, to synthesize compounds of Formula I where Z is a chemical bond and W is alkylene, an optionally substituted carbazole may be reacted in the presence a molar excess of sodium hydride with a haloalkylaryl compound. To synthesize compounds where W is optionally substituted amino or aminoalkylene, the corresponding aryl compound can be employed, e.g. an aminoaryl or alkylaminoaryl compound, can be employed. To prepare compounds where X is a hetero atom, a phenoxazine, phenothiazine or phenazine can be reacted under similar conditions. A diphenylamine can be reacted to provide compounds of Formula IA. See the examples which follow for exemplary reaction conditions.

As discussed above, preferred compounds of the invention exhibit good inhibition activity in a standard dihydrofolate reductase assay. In particular, preferred compounds of the invention exhibit in a standard dihydrofolate reductase assay an IC_{50} (:M) of less than about 50 against rat liver dihydrofolate reductase, and other mammalian including human dihydrofolate reductase; more preferably an IC_{50} (:M) of less than about 25 against rat liver dihydrofolate reductase, and other mammalian including human dihydrofolate reductase; even more preferably an IC_{50} (:M) of less than about 10 against rat liver dihydrofolate reductase, and other mammalian including human dihydrofolate reductase.

Preferred compounds of the invention also include those that exhibit in a standard dihydrofolate reductase assay an IC_{50} (:M) of less than about 20 against *P. carinii* dihydrofolate reductase, more preferably an IC_{50} (:M) of less than about 10 against *P. carinii* dihydrofolate reductase, still more preferably an IC_{50} (:M) of less

than about 5 against *P. carinii* dihydrofolate reductase, even more preferably an IC_{50} (:M) of less than about 1 or 2 against *P. carinii* dihydrofolate reductase. Preferred compounds of the invention also exhibit in a standard dihydrofolate reductase assay an IC_{50} (:M) of less than about 10 against *T. gondii* dihydrofolate reductase, more preferably an IC_{50} (:M) of less than about 5 against *T. gondii* dihydrofolate reductase, still more preferably an IC_{50} (:M) of less than about 1 against *T. gondii* dihydrofolate reductase, even more preferably an IC_{50} (:M) of less than about 0.1 against *T. gondii* dihydrofolate reductase.

Particularly preferred compounds of the invention include those compounds that exhibit selective activity for a targeted disorder or microorganism relative to activity against host proliferative tissue (e.g. bone marrow, oral/intestinal mucosa and the like).

Compounds of the invention may be used in therapy in conjunction with other medicaments. For example, compounds of the invention may be administered in combination with agents used for treatment against parasitic infections and associated diseases and disorders. For instance, compounds of the invention can be administered in conjunction with a sulfa drug such as sulfacetamide, sulfadiazine, sulfadimethoxine, sulfadimidine, sulfamethoxazole, sulfathiazole, sulfaguanidine and the like. However, preferred compounds of the invention will be sufficiently potent to enable effective therapy without use of another active pharmaceutical agent.

Compounds of the invention can be suitably administered to a subject by a variety of routes including oral, parenteral (including intraperitoneal, subcutaneous, intravenous, intradermal or intramuscular injection), topical (including trasdermal, buccal or sublingal), or nasal. Administration also suitably may be via inhalation or rectally. The optimal dose can be determined by conventional means.

Compounds of the present invention are suitably administered to a subject in the protonated and water-soluble form, e.g., as a pharmaceutically acceptable salt of an organic or inorganic acid, e.g., hydrochloride, sulfate, hemi-sulfate, phosphate, nitrate, acetate, oxalate, citrate, maleate, mesylate, etc., or if an acid group is present

on the therapeutic compound, a base addition salt can be employed, e.g. a Na or K salt.

Compounds of the invention can be employed, either alone or in combination with one or more other therapeutic agents as discussed above, as a pharmaceutical composition in mixture with conventional excipient, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral, oral, enteral, topical or intranasal application which do not deleteriously react with the active compounds and are not deleterious to the recipient thereof. Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohol, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, etc. The pharmaceutical preparations can be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously react with the active compounds.

For parenteral application, particularly suitable are solutions, preferably oily or aqueous solutions as well as suspensions, emulsions, or implants, including suppositories. Ampules are convenient unit dosages.

For enteral application, particularly suitable are tablets, dragees or capsules having talc and/or carbohydrate carrier binder or the like, the carrier preferably being lactose and/or corn starch and/or potato starch. A syrup, elixir or the like can be used wherein a sweetened vehicle is employed. Sustained release compositions can be formulated including those wherein the active component is protected with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc.

As discussed above, the compounds of this invention are particularly useful in the treatment of mammalian subjects, e.g. primates particularly humans, to provide treatment from infection a variety of microorganisms including *Toxoplasma gondii*, *Pnemocytis carinii*, *Cryptosporidium* including *Cryptosporidium parvum*, *Leishmania*, *Plasmodium vivax*, *P. falciparum*, *P. malarie*, and *P. ovale*. Such subjects include those afflicted with toxoplasmosis, cryptosporidiosis, leischmaniasis

or malaria. Such subjects often will be immunocompromised, e.g. the subjects may suffer a primary infection from a retrovirus such as human immunodeficiency virus. The patients also may be immunocompromised as a result of other circumstances, e.g. due to cancer therapy.

Compounds of the invention also will be useful for veterinary applications, e.g. to treat mammals such as livestock e.g. cattle, sheep, goats, cows, swine and the like and dogs and cats and other pets and domesticated animals; poultry such as chickens, ducks, geese, turkeys and the like. In particular, the compounds will be useful to treat animals that may carry *T. gondii* such as sheep, pigs and cats.

It will be appreciated that the actual preferred amounts of active compounds used in a given therapy will vary according to the specific compound being utilized, the particular compositions formulated, the mode of application, the particular site of administration, etc. Optimal administration rates for a given protocol of administration can be readily ascertained by those skilled in the art using conventional dosage determination tests conducted with regard to the foregoing guidelines. In general, a suitable effective dose of one or more compounds of Formulae I, IA, II, IIA, III, IV, IVA, will be in the range of from 0.01 to 100 milligrams per kilogram of bodyweight of recipient per day, preferably in the range of from 0.01 to 20 milligrams per kilogram bodyweight of recipient per day, more preferably in the range of 0.05 to 4 milligrams per kilogram bodyweight of recipient per day. The desired dose is suitably administered once daily, or several sub-doses, e.g. 2 to 4 sub-doses, are administered at appropriate intervals through the day, or other appropriate schedule.

All documents mentioned herein are incorporated herein by reference in their entirety. The following non-limiting examples are illustrative of the invention.

Example 1: N-(2,4-Diaminopteridin-6-yl)methyl-N,N-diphenylamine (Formula I: Ar = 2,4-diaminopteridin-6-yl); X = N; W = CH_2; Z = non-linked hydrogens on each phenyl group; m = n = 0).

Powdered NaH (50 mg, 2.1 mmol) is added to a stirred solution of diphenylamine (1.3 g, 0.77 mmol) in dry THF (10 mL) at 0 °C under N_2. After 10 min, 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol) is

added and the reaction mixture is allowed to come to room temperature and left to stir for 2 days. The excess NaH is decomposed with MeOH (1 mL) and the mixture is concentrated to dryness by rotary evaporation. Flash chromatography on silica gel with 95:5 $CHCl_3$-MeOH as the eluent affords the product, N-(2,4-diaminopteridin-6-yl)methyl-N,N-diphenylamine, as a bright-yellow powder (56 mg, 54% yield); mp >250 °C dec.; MS (FAB) *m/z* (M + 1) = 344; IR (KBr) ν 3450, 3340, 3170, 1630, 1590, 1550, 1490, 1450, 1360, 1220 cm^{-1}; ^1H NMR (d_6-DMSO) δ 5.10 (s, 2H, CH_2), 6.70 (m, 10H, aromatic), 8.60 (s, 1H, C_7-H. Anal. Calcd for $C_{19}H_{17}N_7 \cdot 0.8H_2O$: C, 63.73; H, 5.23; N, 27.40. Found: C, 64.15; H, 4.85; N, 27.07.

Example 2: Preparation of 2,4-Diamino-6-(carbazol-5-yl)methylpteridine (Formula I: Ar=6-(2,4-diaminopteridine); X=N; W=CH_2; Z=chemical bond; m=n=0).

NaH (60% oil suspension containing 44 mg. 1.88 mmol) was added to a stirred solution of carbazole (65.5 mg, 0.392 mmol) in dry THF (10 mL) at 0°C under N_2. After 10 minutes, 2,4-diamino-6-bromo-methylpteridine hydrobromide (100 mg, 0.392 mmol) was added and the reaction mixture was allowed to come to room temperature and left to stir for 2 days. The excess NaH was decomposed with several drops of MeOH followed by three drops of glacial AcOH, and the mixture was concentrated to dryness by rotary evaporation. Flash chromatography on silica gel with 85:15 $CHCl_3$-MeOH followed by 1:1 $CHCl_3$-MeOH as the eluent. Appropriate fractions were pooled and evaporated to a yellow solid which was dried in vacuo at 70°C overnight, to provide the title compound, 2,3-diamino-6-(carbazol-5-yl)methylpteridine, yield 10 mg (<10%). MS (FAB) *m/z* (M + 1) = 342.2265. Anal. Calcd. for $C_{19}H_{15}N_7$ 1/6$CHCl_3$: C, 63.72; H, 4.23. Found: C, 63.41; H, 4.11.

Example 3: Preparation of 2,4-Diamino-6-(9,10-dihydroacridin-9-yl)methylpteridine (Formula I: Ar=6-(2,4-diaminopteridine); X=N; W=CH_2; Z=CH_2; m=n=0).

Raney Ni (1 g) was added to a solution of acridine (1 g, 5.58 mmol) in EtOH (20 mL), and the mixture was shaken under a hydrogen atmosphere (50 psi) for 2 days. Additional EtOH (200 mL) was added, and the Ni catalyst was removed by

filtration. Evaporation of filtrate and recrystallization of the residue from MeOH afforded colorless needles of 5,10-dihydroacridine (0.7 g, 70% yield); mp 169-170°C. A portion of this material (0.224 g. 1.18 mmol) was dissolved in dry THF (10 mL) under N_2, and the solution was cooled to 0 °C, and NaH (50% oil suspension containing 0.119 g, 4.7 mmol) was added in small portions with magnetic stirring. After 10 min, 2,4-diamino-6-bromomethylpteridine hydrobromide (0.100 g, 0.392 mmol) was added slowly with continued stirring, and the reaction mixture was allowed to warm to room temperature and stirred overnight. Excess sodium hydride was destroyed with a small drops of AcOH, and the solvents were removed by rotary evaporation. Flash chromatography of the residue on silica gel with 9:1 $ChCl_3$-MeOH as the eluent afforded the title compound, 2,4-diamino-6-(9,10-dihydroacridin-9-yl)methylpteridine, as a yellow-brown solid (ca. 10% yield); mp>250 °C dec. MS (FAB *m/z* (M + 1) = 370.1785.

Example 4: Preparation of N-[(2,4-Diaminopteridin-6-yl)methyl]phenoxazine (Formula I: Ar=6-(2,4-diaminopteridine); X=N; W=CH_2; Z=O; m=n=0).

NaH (60% oil suspension containing 51 mg, 2.0 mmol) was added to a stirred solution of phenoxazine (147 mg, 0.784 mmol) in dry THF (10 mL) at 0 °C under N_2. After 10 min. 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg. 0.392 mmol) was added and the reaction mixture was allowed to come to room temperature and left to stir for 2 days. The excess NaH was decomposed with MeOH (1 mL), and the mixture was concentrated to dryness by rotary evaporation. Flash chromatography on silica gel yielded the title compound, N-[(2,4-diaminopteridin-6-yl)methyl]phenoxazine, as a brown solid; yield 47 mg (34%); mp >250 °C dec. Anal. Calcd. for $C_{19}H_{15}N_7O$ 0.4H_2O: C, 62.60; H, 4.37. Found: C, 62.84; H, 4.10.

Example 5: Preparation of N-[(2,4-Diaminopteridin-6-yl)methyl]phenothiazine (Formula I: Ar=6-(2,4-diaminopteridine); X=N; W=CH_2; Z=S; m=n=0).

NaH (60% oil suspension containing 51 mg. 2.0 mmol) was added to a stirred solution of phenoxazine (159 mg, 0.784 mmol) in dry THF (20 mL) at 0°C under N_2. After 10 min. 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg. 0.392

mmol) was added and the reaction mixture was allowed to come to room temperature and left in stir for 2 days. The excess NaH was decomposed with MeOH (1 mL), and the mixture was concentrated to dryness by rotary evaporation. Flash chromatography on silica gel yielded the title compound, N-[(2,4-diaminopteridin-6-yl)methyl]phenothiazine, as a greenish-yellow solid; yield 20 mg (14%); mp250 °C dec. Anal. Calcd. for $C_{19}H_{19}N_7$ 5/5$CHCl_3$; C, 64.73, H, 4.93, Found: C, 64.55; H 4.90.

Example 6: Preparation of N-[(2,4-Diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*] azepine (Formula I: Ar=6-(2,4-diaminopteridine); X=N; W=CH_2; Z=CH_2CH_2; m=n=0).

NaH (60% oil suspension containing 11 mg, 0.47 mmol) was added to a stirred solution of 9,10-dihydrodibenz[*b,f*]azepine (77 mg. 0.392 mmol) in dry THF (10 mL) at 0 °C under N_2. After 10 minutes, 2,4,diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.392 mmol) was added and the reaction mixture was allowed to come to room temperature and left to stir for 2 days. After the excess NaH was decomposed with a small volume of MeOH, the mixture was poured into H_2O (20 mL) and the product extracted into 85:15 $CHCl_3$-MeOH (3 x 50 mL). The organic layer was dried over Na_2SO_4 and evaporated, and the residue was purified by preparative TLC (silica gel, 85L15 $CHCl_3$-MeOH) to obtain the title compound, N-[(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine, as a yellow solid (35 mg. 24% yield). Anal. Calcd. for $C_{21}H_{19}N_7$ 1/5 $CHCl_3$: C, 64.73; H, 4.93. Found: C, 64.55: H, 4.90.

Example 7: Preparation of N-[(2,4-Diaminopteridin-6-yl)methyl]dibenz[*b,f*] azepine (Formula I: Ar=6-(2,4-diaminopteridine); X=N; W= CH=CH; Z=CH_2; m=n=0).

NaH (60% oil suspension containing 44 mg. 1.88 mmol) was added to a stirred solution of dibenz[*b,f*]azepine (76 mg. 0.392 mmol) in dry THF (10 mL) at 0 °C under N_2. After 10 min, 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg. 0.392 mmol) was added and the reaction mixture was allowed to come to room temperature and left to stir for overnight. After the excess NaH was decomposed with

MeOH (0.5 mL) and 3 drops of glacial AcOH, the mixture was poured into H_2O (20 mL) and the product was extracted into 85:15 $CHCl_3$:MeOH (3 x 50mL). The organic layers was dried over Na_2SO_4 and evaporated and the residue was purified by column chromatography (flash silica gel. 85:15 $CHCl_3$:MeOH) to obtain the title compound, N-[(2,4-diaminopteridin-6-yl)methyl]dibenz[*b,f*]azepine, as a yellow solid (25 mg. 17% yield). MS (FAB) m/z = M + 1) 367.199. Anal. Calcd. for $C_{21}H_{17}N_7$ ¼$CHCl_3$: C,. 64.25; H, 4.38; N. 2468: Found: C, 64.06; H, 4.19, N, 23.82.

Example 8: N-[(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]-N,N-diphenylamine (Formula I: Ar = 2,4-diamiopyrido[2,3-*d*]pyrimidin-6-yl); X = N; W = CH_2; Z = non-linked hydrogens on each phenyl group; Z = CH_2; m = n = 0) is prepared similarly as disclosed in Example 1 above by using N,N-diphenylamine (1.3 g, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[2,3-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 9: N-[(2,4-Diaminopyrido[3,2-*d*]pyrimidine-6-yl)methyl]-N,N-diphenylamine (Formula I: Ar = 2,4-diaminopyrido[3,2-d]pyrimidin-6-yl; X = N; W = CH_2; Z = non-linked hydrogens on each phenyl group; Z = CH_2; m = n = 0) is prepared similarly as disclosed in Example 1 above by using diphenylamine (1.3 g, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[2,3-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 10: N-[(2,4-Diaminoquinazolin-6-yl)methyl]-N,N-diphenylamine (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; X = N; W = CH_2; Z = non-linked hydrogens on each phenyl group; m = n = 0) is prepared similarly as disclosed in Example 1 above by using diphenylamine (1.3 g, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylquinazoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 11: N-[(2,4-Diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine (Formula I: Ar = 2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl; W = CH_2; X = N; Z = non-linked hydrogens on each phenyl group; m = n = 0).

Step 1. A mixture of 2,4-diamino-5-methylthieno[2,3-*d*]pyrimidine (1.3 g, 7.2 mmol) and pivalic anhydride (33 g, 18 mmol) in dry pyridine is refluxed under N_2 overnight, then cooled and evaporated under reduced pressure. The residue is taken up in Et_2O (500 mL), the solution is washed with 5% $NaHCO_3$ (2 x 100 mL), the organic layer is dried and evaporated, and the residue is recrystallized from Et_2O to obtain the 2,4-bis(pivaloylamino) derivative.

Step 2. The 2,4-bis(pivaloylamino) compound (2.6 g, 7.5 mmol) obtained in Step 1 is dissolved in $CHCl_3$ (600 mL), and the solution is cooled to 0 °C and treated with N-bromosuccinimide (1.6 g, 9.0 mmol) and benzoyl peroxide (0.2 g, 0.8 mmol). The solution is stirred overnight at room temperature, treated with additional N-bromosuccinimide (9.1 g, 51 mmol) and benzoyl peroxide (1.2 g, .4.8 mmol), and left to stir for a total of 6 days. The yellow solid which precipitates during this time is filtered off, and the filtrate is washed with H_2O (2 x 50 mL), dried and evapor-ated to obtain 2,4-bis(pivaloylamino)-5-bromomethyl-6-bromothieno[2,3-*d*]pyrimidine.

Step 3. A mixture of 2,4-bis(pivaloylamino)-5-bromomethyl-6-bromothieno[2,3-*d*]pyrimidine prepared in Step 2 above (200 mg, 0.4 mmol), diphenylamine (1.3 g, 0.77 mmol) and NaH (50 mg, 2.1 mmol) in dry THF (10 mL) is stirred at room temperature for 2 days, the excess NaH is decomposed with MeOH (1 mL), the solvent is evaporated, and the residue is chromatographed on silica gel to obtain 2,4-bis(pivaloylamino)-5-(N,N-diphenylaminomethyl)-6-bromothieno[2,3-*d*]pyrimidine.

Step 4. To remove the pivaloyl groups, 2,4-bis(pivaloylamino)-5-(N,N-diphenylaminomethyl)-6-bromothieno[2,3-*d*]pyrimidine prepared in Step 3 above (224 mg, 0.4 mmol) is stirred in a mixture of MeOH (100 mL) and 1 N NaOH (50 mL) at 35 °C overnight. The precipitated solid is collected, washed with H_2O, and air-dried.

Step 5. To remove the remaining bromine atom, a solution of the compound prepared in Step 4 above (118 mg, 0.3 mmol) in 1:1 THF-H_2O (30 mL) is

cooled to 0 °C and treated with $PdCl_2$ (240 mg, 0.6 mmol) and $NaBH_4$ (110 mg, 3.0 mmol). The mixture is left to stir at room temperature for 8 hrs, the THF is evaporated under reduced pressure and replaced with an equal volume of H_2O, and the product is extracted several times with $CHCl_3$. The combined organic layers are dried over Na_2SO_4 and evaporated, and the residue is purified by silica gel chromatography using a mixture of $CHCl_3$ and MeOH as the eluent to afford the desired compound, N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-6-yl)methyl]-N,N-diphenylamine. The final product and its intermediates can be purified by chromatography.

Example 12: N-[(2,4-Diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine (Formula I: Ar = 2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl; W = CH_2; X = N; Z = non-linked hydrogens on each phenyl group; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-6-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using diphenylamine (1.3 g, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-chloromethylfuro[2,3-*d*]pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.

Example 13: N-[(2,4-Diaminopyrimidin-6-yl)methyl-N,N-diphenylamine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH_2; X = N; Z = non-linked hydrogens on each phenyl group; m = n = 0) is prepared similarly to N-(2,4-diaminopteridin-6-yl)methyl-N,N-diphenylamine as disclosed above by using diphenylamine (1.3 g, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-bromomethylpyrimidine hydrobromide (86 mg, 0.3 mmole). The product can be purified by chromatography.

Example 14: N-[(2,4-Diaminopteridin-6-yl)methyl]carbazole (Formula I: Ar = 2,4-diaminopteridin-6-yl; W = CH_2; X = N; Z = chemical bond; m = n = 0) is prepared similarly to N-(2,4-diaminopteridin-6-yl)methyl-N,N-diphenylamine as disclosed above by using carbazole (129 mg, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 15: N-[(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]carbazole (Formula I: Ar = 2,4-diaminopyrido[2,3-d[pyrimidin-6-yl; W = CH_2; X = N; Z = chemical bond; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]N,N-diphenylamine as disclosed above by using carbazole (129 mg, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[2,3-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 16: N-[(2,4-Diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]carbazole (Formula I: Ar = 2,4-diaminopyrido[2,3-d]pyrimidin-6-yl; W = CH_2; X = N; Z = chemical bond; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using carbazole (129 mg, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[3,2-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 17: N-[(2,4-Diaminoquinazolin-6-yl)methyl]carbazole (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = CH_2; N = X; Z = chemical bond; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using carbazole (129 mg, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylquinaoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 18: N-[(2,4-Diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]carbazole (Formula I: Ar = 2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl; W = CH_2; X = N; Z = chemical bond; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using 2,4-diamino-5-methylthieno[2,3-*d*]pyrimidine (1.3 g, 7.2 mmol) in Step 1 and carbazole (129 mg, 0.8 mmol) in Step 3. The final product and its intermediates can be purified by chromatography.

Example 19: N-[(2,4-Diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]carbazole (Formula I: Ar = 2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl; W = CH_2; X = N; Z = chemical bond; m = n = 0) is prepared similarly to N-[(2,4-diaminofuro[2,3-

d]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using carbazole (129 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-chloromethylfuro[2,3-*d*]pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.

Example 20: N-[(2,4-Diaminopyrimidin-6-yl)methyl]carbazole (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH_2; X = N; Z = chemical bond; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using carbazole (129 mg, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-bromomethylpyrimidine hydrobromide (86 mg, 0.3 mmol). The product can be purified by chromatography.

Example 21: N-[(2,4-Diaminopteridin-6-yl)methyl]-9,10-dihydroacridine (Formula I: Ar = 2,4-diaminopteridin-6-yl; W = CH_2; N = X; Z = CH_2; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydroacridine (134 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 22: N-[(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]-9,10-dihydroacridine (Formula I: Ar = 2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl; W = CH_2; X = N; Z = CH_2; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydroacridine (134 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[2,3-d]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 23: N-[(2,4-Diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]-9,10-dihydroacridine (Formula I: Ar = 2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl; W = CH_2; X = N; Z = CH_2; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydroacridine (134 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[3,2-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 24: N-[(2,4-Diaminoquinazolin-6-yl)methyl]-9,10-dihydroacridine (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = CH_2; X = N; Z = CH_2; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydroacridine (134 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylquinazoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 25: N-[(2,4-Diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydroacridine (Formula I: Ar = 2,4-diaminothieno[2,3-*d*]pyrimidi-5-yl; W = CH_2; X = N; Z = CH_2; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using 2,4-diamino-5-methylthieno[2,3-*d*]pyrimidine (1.3 g, 7.4 mmol) in Step 1 and 9,10-dihydroacridine (134 mg, 0.8 mmol) in Step 3. The final product and its intermediates can be purified by chromatography.

Example 26: N-[(2,4-Diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydroacridine (Formula I: Ar = 2,4-diaminofuro[2,3-$_2$]pyrimidin-5-yl; W = CH_2; X = N; Z = CH_2; m = n = 0) is prepared similarly to N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using 9,10-dihydroacridine (134 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-chloromethylfuro[2,3-*d*]pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.

Example 27: N-[(2,4-Diaminopyrimidin-6-yl)methyl]-9,10-dhydroacridine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH_2; X = N; Z = CH_2; m = = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydroacridine (134 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-bromomethylpyrimidine hydrobromide (86 mg, 0.3 mmol). The product can be purified by chromatography.

Example 28: N-[(2,4-Diaminopteridin-6-yl)methyl]phenoxazine (Formula I: Ar = 2,4-diaminopteridin-6-yl; W = CH_2; X = N; Z = O; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenoxazine (146 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-

diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol). The final product can be purified by chromatography.

Example 29: 9-[(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]phenoxazine (Formula I: Ar = 2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl; W = CH_2; X = N; Z = O; m = = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenoxazine (146 mg,0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[2,3-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 30: 9-[(2,4-Diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]phenoxazine (Formula I: Ar = 2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl; W = CH_2; X = N; Z = O; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenoxazine (146 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[3,2-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 31: 9-[(2,4-Diaminoquinazolin-6-yl)methyl]phenoxazine (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = CH_2; X = N; Z = O; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenoxazine (146 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylquinazoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 32: 9-[(2,4-Diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]phenoxazine (Formula I: Ar = 2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl; W = CH_2; X = N; Z = O; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using 2,4-diamino-5-methylthieno[2,3-*d*]pyrimidine (1.3 g, 7.4 mmol) in Step 1 and phenoxazine (146 mg, 0.8 mmol) in Step 3. The final product and its intermediates can be purified by chromatography.

Example 33: 9-[(2,4-Diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]phenoxazine (Formula I: Ar = 2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl; W = CH_2; X = N; Z = O; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using phenoxazine (146 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-chloromethylfuro[2,3-*d*]pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.

Example 34: 9-[(2,4-Diaminopyrimidin-6-yl)methyl]phenoxazine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH_2; X = N; Z = O; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenoxazine (146 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-bromomethylpyridine hydrobromide (86 mg, 0.3 mmol). The product can be purified by chromatography.

Example 35: N-[(2,4-Diaminopteridin-6-yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminopteridin-6-yl; W = CH_2 X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenothiazine (159 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 36: 9-[(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminopyrido[2,3- *d*]pyrimidin-6-yl; W = CH_2; X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by starting from phenothiazine (159 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[2,3-d]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 37: 9-[(2,4-Diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl; W = CH_2; X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenothiazine (159 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[3,2-

d]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 38: 9-[(2,4-Diaminoquinazolin-6-yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = CH_2; X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenothiazine (159 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylquinazoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 39: 9-[(2,4-Diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl; W = CH_2; X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenyl-amine as disclosed in Example 11 above by using 2,4-diamino-5-methylthieno[2,3-*d*]pyrimidine (1.3 g, 7.4 mmol) in Step 1 and phenothiazine (159 mg, 0.8 mmol) in Step 3. The final product and its intermediates can be purified by chromatography.

Example 40: 9-[(2,4-Diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl; W = CH_2; X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed above by using phenothiazine (159 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-chloromethylfuro[2,3-*d*]pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.

Example 41: 9-[(2,4-Diaminopyrimidin-5-yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH_2; X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenothiazine (159 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-bromomethylpyridine hydrobromide (86 mg, 0.3 mmol). The product can be purified by chromatography.

Example 42: N-[(2,4-Diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine (Formula I: Ar = 2,4-diaminopteridiin-6-yl; W = CH_2; X

= N; Z = CH_2CH_2; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydrodibenz[*b,f*]azepine (158 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 43: 9-[(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]-9,10-dihydrodibenz-[*b,f*]azepine (Formula I: Ar = 2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl; W = CH_2; X = N; Z = CH_2CH_2; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydrodibenz[*b,f*]azepine (158 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol) and 2,4-diamino-6-bromomethylpyrido[2,3-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 44: 9-[(2,4-Diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]-9,10-dihydrodibenz-[*b,f*]azepine (Formula I: Ar = 2,4-diaminopyrido[3,2-d]pyrimidin-6-yl; W = CH_2; X = N; Z = CH_2CH_2; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydrodibenz[*b,f*]azepine (158 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[3,2-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 45: 9-[(2,4-Diaminoquinazolin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = CH_2; X = N; Z = CH_2CH_2; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydrodibenz[*b,f*]azepine (158 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylquinazoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 46: 9-[(2,4-Diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydrodibenz-[*b,f*]azepine (Formula I: Ar = 2,4-diaminohieno[2,3-*d*]pyrimidi-5-yl; W = CH_2; X = N; Z = CH_2CH_2; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in

Example 11 above, by using 2,4-diamino-5-methylthieno[2,3-*d*]pyrimidine (1.3 g, 7.4 mmol) in Step 1 and 9,10-dihydrodibenz[*b,f*]azepine (158 mg, 0.8 mmol) in Step 3. The final product and its intermediates can be purified by chromatography.

Example 47: 9-[(2,4-Diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydrodibenz-[*b,f*]azepine (Formula I: Ar = 2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl; W = CH_2; X = N; Z = CH_2CH_2; m = n = 0) is prepared similarly to N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydrodibenz[*b,f*]azepine (158 mg, 0.8 mmol), sodium hydride (50 mg, 2.1 mmol), and 2,4-diamino-5-chloromethylfuro[2,3-*d*]-pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.

Example 48: 9-[(2,4-Diaminopyrimidin-5-yl)methyl]-9,10-dhydrodibenz[*b,f*]azepine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH_2; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydrodibenz[*b,f*]azepine (158 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-bromomethylpyrimidine hydrobromide (86 mg, 0.3 mmol). The product can be purified by chromatography.

Example 49: N-[(2,4-Diaminopteridin-6-yl)methyl]dibenz[*b,f*]azepine (Formula I: Ar = 2,4-diaminopteridin-6-yl; W = CH_2; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above, by using dibenz[*b,f*]azepine (154 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 50: 9-[(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]dibenz[*b,f*]azepine (Formula I: Ar = 2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl; W = CH_2; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using dibenz[*b,f*]azepine (154 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[2,3-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 51: 9-[(2,4-Diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]dibenz[*b*,*f*]azepine (Formula I: Ar = 2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl; W = CH_2; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using dibenz[*b*,*f*]azepine (154 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[3,2-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 52: 9-[(2,4-Diaminoquinazolin-6-yl)methyl]dibenz[*b*,*f*]azepine (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = CH_2; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using dibenz[*b*,*f*]azepine (154 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylquinazoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 53: 9-[(2,4-Diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]dibenz[*b*,*f*]azepine (Formula I: Ar = 2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl; W = CH_2; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed above by using 2,4-diamino-5-methylthieno[2,3-*d*]pyrimidine (1.3 g, 7.4 mmol) in Step 1 and dibenz[*b*,*f*]azepine (154 mg, 0.8 mmol) in Step 3. The final product and its intermediates can be purified by chromatography.

Example 54: 9-[(2,4-Diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]benz[*b*,*f*]azepine (Formula I: Ar = 2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl; W = CH_2; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed above by using dibenz[*b*,*f*]azepine (154 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-chloromethylfuro[2,3-d[pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.

Example 55: 9-[(2,4-Diaminopyrimidin-6-yl)methyl]dibenz[*b*,*f*]azepine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH_2; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine

as disclosed above by using dibenz[*b,f*]azepine (154 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-bromomethylpyrimidine hydrobromide (86 mg, 0.3 mmol). The product can be purified by chromatography.

Example 56: N-(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)benzhydrylamine (Formula I: Ar = 2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl; W = NH; X = CH; Z = non-linked hydrogens on each phenyl group; m = n = 0).

A solution of benzhydrylamine (366 mg, 2.0 mmol) and 2,4,6-triaminopyrido[2,3-*d*]pyrimidine (350 mg, 2.0 mmol) in a mixture of DMF (40 mL) and glacial AcOH (4 mL) is treated with $BH_3 \cdot Et_3N$ (75 mg, 6.6 mmol), and the mixture is stirred at room temperature overnight, then diluted with H_2O (20 mL) to decompose any unreacted reducing agent. The solvents are evaporated under reduced pressure, and the residue is purified on a silica gel column using 5-15% $CHCl_3$ in MeOH as the eluent. Pooling and evaporation of appropriate fractions yields the title compound, N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)benzhydrylamine.

Example 57: N-[(2,4-Diaminoquinazolin-6-yl)amino]benzhydrylamine (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = NH; X = CH; Z = non-linked hydrogens on each phenyl group; m = n = 0) is prepared similarly to N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]benzhydrylamine as disclosed above by using benzhydrylamine (366 mg, 2.0 mmol), 2,4,6-triaminoquinazoline (350 mg, 2.0 mmol), and $BH_3 \cdot Et_3N$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 58: N-[(2,4-Diaminopyrimidin-5-yl)methyl]benzhydrylamine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl); W = CH_2NH; X = CH; Z = non-linked hydrogens on each phenyl group; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]benzhydrylamine as disclosed above by using benzhydrylamine (366 mg, 2.0 mmol), 2,4-diamino-5-aminomethylpyrimidine (278 mg, 2.0 mmol), mg, 2 mmol), and $BH_3 \cdot Et_3N$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 59: N-[(2,4-Diaminopyrimidin-5-yl)ethyl]benzhydrylamine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH_2CH_2NH; X = CH; Z = non-linked hydrogens on each phenyl group; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-*d*]pyri-midin-6-yl)amino]benzhydrylamine as disclosed above by using benzhydrylamine (366 mg, 2.0 mmol), 2,4-diamino-5-(2-aminoethyl)pyrimidine (306mg, 2.0 mmol), mg, 2.0 mmol), and $BH_3 \cdot Et_3N$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 60: 9-[N-(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]fluorene (Formula I: Ar = 2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl; W = NH; X = CH; Z = chemical bond; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]benzhydrylamine as disclosed above by using fluorenone (360 mg, 2.0 mmol), 2,4,6-triaminopyrido[2,3-*d*]pyrimidine (350 mg, 2.0 mmol), mg, 2.0 mmol), and $BH_3 \cdot Et_3N$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 61: 9-[N-(2,4-Diaminoquinazolin-6-yl)amino]fluorene (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = NH; Z = CH; Z = chemical bond; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)amino]fluorene as disclosed above by using fluorenone (360 mg, 2.0 mmol), 2,4,6-triaminoquinazoline (350mg, 2.0 mmol), and $BH_3 \cdot Et_3N$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 62: 9-[N-(2,4-Diaminopyrimidin-5-yl)methylamino]fluorene (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH_2NH is prepared similarly to N-(2,4-diaminopyrido-[2,3-*d*]pyrimidin-6-yl)amino]fluorene as disclosed above by using fluorenone (360 mg, 2.0 mmol), 2,4-diamino-5-aminomethylpyrimidine (278 mg, 2.0 mmol), and $BH_3 \cdot Et_3N$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 63: 9-[N-[2-(2,4-Diaminopyrimidin-5-yl)ethyl]amino]fluorene (Formula I: Ar = 2,4-diaminopyrimidin-5-yl); W = CH_2CH_2NH; X = CH; Z = chemical bond; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-

d]pyrimidin-6-yl)amino]fluorene as disclosed above by using fluorenone (360 mg, 2.0 mmol), 2,4-diamino-5-(2-aminoethyl)pyrimidine (306 mg, 2.0 mmol), and $BH_3 \cdot Et_3N$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 64: 5-[N-(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]-5*H*-10,11-dihydro-dibenzo[*a*,*d*]cycloheptene (Formula I: Ar = 2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl; W = NH; X = CH; Z = CH_2CH_2; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido-[2,3-*d*]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5*H*-dibenzo[*a*,*d*]cycloheptene-5-one (416 mg, 2.0 mmol), 2,4,6-triaminopyrido[2,3-*d*]pyrimidine (350 mg, 2.0 mmol), and $BH_3 \cdot Et_3N$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 65: 5-[N-(2,4-Diaminoquinazolin-6-yl)amino]-5*H*-10,11-dihydrodibenzo[*a*,*d*]-cycloheptene (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = NH; X = CH; Z = CH_2CH_2; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5*H*-dibenzo[*a*,*d*]cycloheptane-5-one (416 mg, 2.0 mmol), 2,4,6-triaminoquinazoline (350 mg, 2.0 mmol), and $BH_3 \cdot Et_3N$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 66: 5-[N-(2,4-Diaminopyrimidin-5-yl)methylamino]-5*H*-10,11-dihydro-dibenzo[*a*,*d*]heptene (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH_2NH; Z = CH_2CH_2; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5*H*-dibenzo[*a*,*d*]cycloheptan-5-one (416 mg, 2.0 mmol), 2,4-diamino-5-aminomethylpyrimidine (278 mg, 2.0 mmol), and $BH_3 \cdot Et_3N$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 67: 5-[N-[2-(2,4-Diaminopyrimidin-5-yl)ethyl]amino]-5*H*-10,11-dihydro-dibenzo[*a*,*d*]cycloheptene (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH_2CH_2NH; X = CH; Z = CH=CH; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5*H*-dibenzo[*a*,*d*]cycloheptan-5-one (416 mg, 2.0 mmol), 2,4-diamino-5-(2-

aminoethyl)pyrimidine (306 mg, 2.0 mmol), and $BH_3 \cdot Et_3N$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 68: 5-[N-(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]-5*H*-dibenzo[*a*,*d*]-cycloheptene (Formula I: Ar = 2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl; W = NH; X = CH; Z = CH=CH; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5*H*-dibenzo[*a*,*d*]cyclohepten-5-one (412 mg, 2.0 mmol), 2,4,6-triaminopyrido[2,3-*d*]pyrimidine (350 mg, 2.0 mmol), and $BH_3 \cdot Et_3N$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 69: 5-[N-(2,4-Diaminoquinazolin-6-yl)amino]-5*H*-dibenzo[*a*,*d*]cycloheptene (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = NH; X = CH; Z = CH=CH; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5*H*-dibenzo[*a*,*d*]cycloheptan-5-one (412 mg, 2.0 mmol), 2,4,6-triaminoquinazoline (350 mg, 2.0 mmol), and $BH_3 \cdot Et_3N$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 70: 5-[N-(2,4-Diaminopyrimidin-5-yl)methylamino]-5*H*-dibenzo[*a*,*d*]heptene (Formula I: Ar = 2,4-diaminopyrmidin-5-yl; W = CH_2NH; X = CH; Z = chemical bond; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5*H*-dibenzo[*a*,*d*]cycloheptan-5-one (412 mg, 2.0 mmol), 2,4-diamino-5-aminomethylpyrimidine (278 mg, 2.0 mmol), and $BH_3 \cdot Et_3N$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 71: 5-[N-[2-(2,4-Diaminopyrimidin-5-yl)ethyl]amino]-5*H*-dibenzo[*a*,*d*]heptene (Formula I: Ar = 2,4-diaminopyrimidin-5-yl); W = CH_2CH_2NH; X = CH=CH; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5*H*-dibenzo[*a*,*d*]cycloheptan-5-one (412 mg, 2.0 mmol), 2,4-diamino-5-(2-

aminoethyl)pyrimidine (306 mg, 2.0 mmol), and $BH_3 \cdot Et_3N$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 72: Dihydrofolate reductase inhibition

Compounds of the invention were tested for inhibition of dihydrofolate reductase (DHFR) from rat liver, *Pneumocystis carinii* and *Toxoplasmosis gondii*. IC_{50} values were determined, which is the concentration (:M) of a compound required to inhibit the dihydrofolate reductase activity by 50%. Selectivity ratios are also set forth in the table. The DHFR inhibition assay was conducted by the procedures disclosed in Broughton, M.C. et al., *Antimicrob. Agents Chemother.*, 1991, 35: 1348-1355; Chio, L.C. et al., *Antimicrob. Agents Chemother.*, 1993, 37: 1914-1923. Results are set forth in Table 1 below, with the tested compound identified by reference to the structural formula set forth at the top of the table.

Table 1. Inhibition of *Pneumocystis carinii*, *Toxoplasma gondii*, and rat liver dihydrofolate reductase by compounds of the invention.



cmpd	X		DHFR inhibition (IC_{50} μM)[c]			selectivity ratio	
			P.carinii	*T.gondii*	rat liver	rat liver/ *P.carinii*	rat liver/ *T. gondii* liver
1	a		4.9	1.3	2.8	0.57	2.2
2	b		0.10	0.055	0.012	0.55	0.022
3	CH_2		0.042	0.029	0.027	0.64	0.93
4	O		3.4	2.2	13	3.8	5.9
5	S		0.12	0.11	0.20	1.7	1.8
6[c]	CH_2CH_2	expt 1	1.7	0.89	4.4		
		expt 2	1.0	0.93	2.7		
		mean	1.4	0.91	5.1	3.6	5.6
7[c]	CH=CH	expt 1	0.24	0.010	2.1		
		expt 2	0.18	0.041	9.3		
		expt 3		0.084	4.4		
		mean	0.21	0.045	5.3	25	118

[a] No bridge between the phenyl rings (i.e. X is non-linked hydrogens)

[b] Direct bridge between the phenyl rings (i.e. X is a chemical bond)

[c] Replicate assays performed on different days

Example 73: Additional data of N-[2,4-diaminopteridin-6-yl)methyldibenz [*b,f*]azepine

It was also found that N-[2,4-diaminopteridin-6-yl)methyldibenz[*b,f*]azepine inhibited the proliferation of *T. gondii* cells in culture as measured by a standard assay based on [^{3}H]uracil incorporation into the acid-insoluble fraction. The assay protocol is disclosed in Chio, L.C. et al., *Antimicrob. Agents Chemother.*, 1993, 37: 1914-1923. Incorporation relative to untreated controls was inhibited by 90% at a concentration of N-[2,4-diaminopteridin-6-yl)methyldibenz[*b,f*]azepine of 1 micromolar and the IC_{50} was about 0.3 micromolar. A typical IC_{50} for current antixoplasmosis clinic agent pyrimethamine in this assay is 0.5-0.8 micromolar. It thus appears that N-[2,4-diaminopteridin-6-yl)methyldibenz[*b,f*] azepine is at least as active as pyrimethamine in this assay.

The ratio IC_{50}(uracil incorporation)/IC_{50} (DHFR inhibition) can indicate the efficiently of drug uptake by a parasite. In the case of the clinical agent pyrimethamine, this ratio is about 1.7. In the case of N-[2,4-diaminopteridin-6-yl)methyldibenz[*b,f*]azepine, whose IC_{50} (DHFR inhibition) is 0.045 micromolar and whose IC_{50} (uracil incorporation) is about 0.3 micromolar, the ratio calculated from these data is 6.7. That indicates that the uptake of N-[2,4-diaminopteridin-6-yl)methyldibenz[*b,f*]azepine is about four times more efficient than that of pyrimethamine.

N-[2,4-diaminopteridin-6-yl)methyldibenz[*b,f*]azepine is also active against intact *P. carinii* cells as measured by a different assay based on incorporation of [^{3}H]para-aminobenzoic acid (PABA) into the total cellular folate pool of freshly harvested cells from a rat. The assay protocol that was employed is described in Kovacs, J.A., et al., *J. Infect. Dis.*, 1989, 160: 312-320; and Chio, L.C. et al., *Antimicrob. Agents Chemother.*, 1993, 37: 1914-1923. This assay can be used as measure of cell viability after drug treatment, and relies on the fact that *P.carinii* do not take up exogenous folates but can make their own folates de novo from PABA. After 5 hours of treatment with 17.6 micromolar N-[2,4-diaminopteridin-6-yl)methyldibenz[*b,f*]azepine there was about a 60% decrease in uptake of [^{3}H]PABA

relative to controls. From this data, it can be estimated that the growth inhibitory concentration of N-[2,4-diaminopteridin-6-yl)methyldibenz[*b,f*]azepine against *P. carinii* in an established culture is about 10 micromolar or less depending on the length of treatment.

Example 74: Inhibition of dihyrofolate reductase (DHFR) from *Mycobacterium avium*

Compounds of the invention were tested for inhibition of dihydrofolate reductase (DHFR) from *Mycobacterium avium* (*M. avium*), an organism which has been used to screen drug candidates for activity against tuberculosis. IC_{50} values were determined, which is the concentration (:M) of a compound required to inhibit the specified dihydrofolate reductase activity by 50%. Selectivity ratios also are were determined and set forth in the table, which are calculated as the ratio of IC_{50} rat liver to IC_{50} *M.avium*. The DHFR inhibition assay was conducted by the procedures disclosed in Broughton, M.C. et al., *Antimicrob. Agents Chemother.*, 1991, 35: 1348-1355; Chio, L.C. et al., *Antimicrob. Agents Chemother.*, 1993, 37: 1914-1923. Results are set forth in Table 2 below, with the tested compound identified by reference to the structural formula set forth at the top of the table (substituent X specified in Table 2), IC50 values (expressed in:M) against rat liver DHFR and *M. avium* DHFR, followed by the selectivity index.

Table 2. Inhibition of dihydrofolate reductase from *Mycobacterium avium*



Cmpd	X	rat liver DHFR	*M. avium* DHFR	Selectivity Index
1	CH=CH	2.1	0.012	175
2	a	4.0	3.7	1.1
3	CH_2	0.027	0.017	1.6
4	O	13	2.5	5.2
5	S	0.20	0.029	6.9

[a] No bridge between the phenyl rings (i.e. X is non-linked hydrogens)

The invention has been described in detail with reference to preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of this disclosure, may make modifications and improvements within the spirit and scope of the invention as set forth in the following claims.

What is claimed is:

1. A compound of the following Formula I:



I

wherein Ar is optionally substituted carbocyclic aryl or optionally substituted heteroaromatic;

W is a chemical bond, optionally substituted amino, optionally substituted alkylene having 1 to about 3 carbon atoms, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms;

X is nitrogen or carbon;

Z represents a chemical bond, optionally substituted methylene, optionally substituted ethylene, optionally substituted vinyl, optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents non-linked substituents on each phenyl group;

each R^1 and R^2 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;

m and n are each independently an integer of from 0 to 4; and pharmaceutically acceptable salts thereof.

2. A compound of the following Formula IA:



IA

wherein Ar is optionally substituted carbocyclic aryl or optionally substituted heteroaromatic;

W is a chemical bond, optionally substituted amino, optionally substituted alkylene having 1 to about 3 carbon atoms, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms;

X is nitrogen or carbon;

Z represents a chemical bond, optionally substituted methylene, optionally substituted ethylene, optionally substituted vinyl, optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents non-linked substituents on each phenyl group;

each R^1 and R^2 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;

m and n are each independently an integer of from 0 to 5; and pharmaceutically acceptable salts thereof.

3. A compound of the following Formula II:



II

wherein Ar is optionally substituted carbocyclic aryl or optionally substituted heteroaromatic;

Z represents a chemical bond, optionally substituted methylene, optionally substituted ethylene, optionally substituted vinyl, optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents non-linked substituents on each phenyl group;

X is nitrogen or carbon;

each R^1 and R^2 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;

m and n are each independently an integer of from 0 to 4; and pharmaceutically acceptable salts thereof.

4. A compound of the following Formula IIA:



IIA

wherein Ar is optionally substituted carbocyclic aryl or optionally substituted heteroaromatic;

Z represents a chemical bond, optionally substituted methylene, optionally substituted ethylene, optionally substituted vinyl, optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents non-linked substituents on each phenyl group;

X is nitrogen or carbon;

each R^1 and R^2 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;

m and n are each independently an integer of from 0 to 4; and pharmaceutically acceptable salts thereof.

5. A compound of the following Formula III:



III

T, U and V are each independently optionally substituted carbon, or optionally substituted nitrogen;

W is a chemical bond, optionally substituted amino, optionally substituted alkylene having 1 to about 3 carbon atoms, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms;

X is nitrogen or carbon;

Z represents a chemical bond, optionally substituted methylene, optionally substituted ethylene, optionally substituted vinyl, optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents non-linked substituents on each phenyl group;

each R^1, R^2 and R^3 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;

m and n are each independently an integer of from 0 to 4; o is an integer of from 0 to 5 and pharmaceutically acceptable salts thereof.

6. A compound of the following Formula IV:



IV

U and V are each independently optionally substituted carbon, or optionally substituted nitrogen;

W is a chemical bond, optionally substituted amino, optionally substituted alkylene having 1 to about 3 carbon atoms, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms;

X is nitrogen or carbon;

Z represents a chemical bond. optionally substituted methylene. optionally substituted ethylene, optionally substituted vinyl, optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents non-linked substituents on each phenyl group;

each R^1 and R^2 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;

m and n are each independently an integer of from 0 to 4; and pharmaceutically acceptable salts thereof.

7. A compound of the following Formula IVA:



IVA

U and V are each independently optionally substituted carbon, or optionally substituted nitrogen;

W is a chemical bond, optionally substituted amino, optionally substituted alkylene having 1 to about 3 carbon atoms, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms;

X is nitrogen or carbon;

Z represents a chemical bond, optionally substituted methylene, optionally substituted ethylene, optionally substituted vinyl, optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents non-linked substituents on each phenyl group;

each R^1 and R^2 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;

m and n are each independently an integer of from 0 to 4; and pharmaceutically acceptable salts thereof.

8. A compound of any one of claims 1, 3, 4, 5, 6 or 7 wherein Z is $-CH_2-$, $-CH_2CH_2-$, NH, O, or S.

9. A compound of any one of claims 1, 2, 5, 6 or 7 wherein W is a bond, CH_2, CH_2CH_2, or NH.

10. A compound of claim 1 wherein the compound is:

N-(2,4-diaminopteridin-6-yl)methyl-N,N-diphenylamine;

2,4-diamino-6-(carbazol-5-yl)methylpteridine;

2,4-diamino-6-(9,10-dihydroacridin-9-yl)methylpteridine;

N-[(2,4-diaminopteridin-6-yl)methyl]phenoxazine;

N-[(2,4-diaminopteridin-6-yl)methyl]phenothiazine;

N-[(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;

N-[(2,4-diaminopteridin-6-yl)methyl]dibenz[*b,f*]azepine;

N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]-N,N-diphenylamine;

N-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]-N,N-diphenylamine;

N-[(2,4-diaminoquinazolin-6-yl)methyl]-N,N-diphenylamine;

N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine;

N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine;

N-[(2,4-diaminopyrimidin-6-yl)methyl-N,N-diphenylamine;

N-[(2,4-diaminopteridin-6-yl)methyl]carbazole;

N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]carbazole;

N-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]carbazole;

N-[(2,4-diaminoquinazolin-6-yl)methyl]carbazole;

N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]carbazole;

N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]carbazole;

N-[(2,4-diaminopyrimidin-6-yl)methyl]carbazole;

N-[(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydroacridine;

N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]-9,10-dihydroacridine;

N-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]-9,10-dihydroacridine;

N-[(2,4-diaminoquinazolin-6-yl)methyl]-9,10-dihydroacridine;

N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydroacridine;

N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydroacridine;

N-[(2,4-diaminopyrimidin-6-yl)methyl]-9,10-dihydroacridine;

N-[(2,4-diaminopteridin-6-yl)methyl]phenoxazine;

9-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]phenoxazine;

9-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]phenoxazine;

9-[(2,4-diaminoquinazolin-6-yl)methyl]phenoxazine;

9-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]phenoxazine;

9-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]phenoxazine;

9-[(2,4-diaminopyrimidin-6-yl)methyl]phenoxazine;

N-[(2,4-diaminopteridin-6-yl)methyl]phenothiazine;

9-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]phenothiazine;

9-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]phenothiazine;

9-[(2,4-diaminoquinazolin-6-yl)methyl]phenothiazine;

9-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl]phenothiazine;

9-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]phenothiazine;

9-[(2,4-diaminopyrimidin-5-yl)methyl]phenothiazine;

N-[(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[*b*,*f*]azepine;

N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]-9,10-dihydrodibenz[*b*,*f*]azepine;

N-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]-9,10-dihydrodibenz[*b*,*f*]azepine;

9-[(2,4-diaminoquinazolin-6-yl)methyl]-9,10-dihydrodibenz[*b*,*f*]azepine;

9-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydrodibenz[*b*,*f*]azepine;

9-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydrodibenz[*b*,*f*]azepine;

9-[(2,4-diaminopyrimidin-5-yl)methyl]-9,10-dihydrodibenz[*b*,*f*]azepine;

N-[(2,4-diaminopteridin-6-yl)methyl]dibenz[*b*,*f*]azepine;

9-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]dibenz[*b*,*f*]azepine;

9-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]dibenz[*b*,*f*]azepine;

9-[(2,4-diaminoquinazolin-6-yl) methyl]dibenz[*b,f*]azepine;

9-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]dibenz[*b,f*]azepine;

9-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]dibenz[*b,f*]azepine;

9-[(2,4-diaminopyrimidin-6-yl)methyl]dibenz[*b,f*]azepine;

N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)benzhydrylamine;

N-(2,4-diaminoquinazolin-6-yl)benzhydrylamine;

N-[(2,4-diaminopyrimidin-5-yl)methyl]benzhydrylamine;

N-[(2,4-diaminopyrimidin-5-yl)ethyl]benzhydrylamine;

9-[N-(2,4-diaminoquinazolin-6-yl)amino]fluorene;

9-[N-(2,4-diaminoquinazolin-5-yl)methylamino]fluorene;

9-[N-[2-(2,4-diaminoquinazolin-5-yl)ethyl]amino]fluorene;

5-[N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]-5*H*-10,11-dihydro-dibenzo[*a,d*]cycloheptene;

5-[N-(2,4-diaminoquinazolin-6-yl)amino]-5*H*-10,11-dihydrodibenzo[*a,d*]cycloheptene;

5-[N-(2,4-diaminopyrimidin-5-yl)methylamino]-5*H*-10,11-dihydrodibenzo [*a,d*]cycloheptene;

5-[N-[2-(2,4-diaminopyrimidin-5-yl)ethyl]amino]-5*H*-10,11-dihydrodibenzo [*a,d*]cycloheptene;

5-[N-(2,4-diaminopyrimidin-[2,3-*d*]pyrimidin-6-yl)amino]-5*H*-dibenzo [*a,d*]cycloheptene;

5-[N-(2,4-diaminoquinazolin-6-yl)amino]-5*H*-dibenzo [*a,d*]cycloheptene;

5-[N-(2,4-diaminopyrimidin-5-yl)methylamino]-5*H*-dibenzo[*a,d*]cycloheptene; and

5-[N-[2-(2,4-diaminopyrimidin-5-yl)ethyl]amino]-5*H*-dibenzo[*a,d*]cycloheptene; and

pharmaceutically acceptable salts thereof.

11. A method of treating a patient suffering from or susceptible to a parasitic disease, comprising administering to the patient an effective amount of a compound of any one of claim 1-10.

12. A method of treating a patient suffering from or susceptible to toxoplasmosis, comprising administering to the patient an effective amount of a compound of any one of claim 1-10.

13. The method of claim 11 or 12 wherein the patient's immune system is suppressed.

14. The method of claim 11 or 12 wherein the patient has a retrovirus infection.

15. The method of claim 11 or 12 wherein the patient has an HIV infection.

16. The method of claim 11 or 12 wherein the patient is suffering from AIDS.

17. The method of claim 11 or 12 wherein the patient has received or will be receiving immunosuppressive cancer chemotherapy treatment.

18. A method of treating a patient suffering from or susceptible to cryptosporidiosis, leischmaniasis or malaria, comprising administering to the patient an effective amount of a compound of any one of claims 1-10.

19. A method of treating a patient suffering from or susceptible to an infection of *Toxoplasma gondii*, *Pnemocytis carinii*, *Cryptosporidium*, *Leishmania*, *Plasmodium vivax*, *P. falciparum*, *P. malarie*, or *P. ovale*.

20. A method of treating a patient suffering from or susceptible to a *Toxoplasma gondii* infection.

21. A method of treating a patient suffering from or susceptible to tuberculosis.

22. A method of any one of claims 11-21 wherein the disease is treated without administration of a sulfa drug to the patient.

23. The method of any one of claims 11-22 wherein the patient is a mammal.

24. A method of any one of claims 11-22 wherein the patient is a human.

25. A method of claim 11, 12 or 20 wherein the patient is a livestock animal, poultry or a domesticated animal.

26. A pharmaceutical composition a pharmaceutically acceptable carrier and a compound of any one of claims 1-10.

Docket No. 48460/70157

Declaration and Power of Attorney for Patent Application
English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor(s) (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"Pharmaceutically Active Compounds and Methods of Use Thereof"

the specification of which

(check one)

[ ] is attached hereto.

[X] was filed on July 26, 2001, as United States Application No. Application No. 09/890,112, based on PCT Application No. PCT/US001968 and was amended on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign Application(s) for patent or inventor(s)'s certificate, or Section 365(a) of any PCT International Application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign Application for patent or inventor(s)'s certificate or PCT International Application having a filing date before that of the Application on which priority is claimed.

Prior Foreign Application(s) — Priority Not Claimed

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional Application(s) listed below:

60/117,321 (Application Serial No.) — Priority Date: 26 January 1999 (26.01.99) (Filing Date)

I hereby claim the benefit under 35 U.S.C. Section 120 of the United States Application(s), or Section 365(c) of any PCT International Application designating the United States, listed below and, insofar as the subject matter of each of the claims of this Application is not disclosed in the prior United States or PCT International Application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark office all information known to me to be material to patentability as defined in Title 37, C.F.C., Section 1.56 which became available between the filing date of the prior Application and the national or PCT International filing date of this Application:

PCT/US00/01968		
(Application Serial No.)	January 25, 2000 (Filing Date)	Pending (Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the Application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this Application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

David G. Conlin	Reg. No. 27,026
George W. Neuner	Reg. No. 26,964
Linda M. Buckley	Reg. No. 31,003
Peter J. Manus	Reg. No. 26,766
Peter F. Corless	Reg. No. 33,860
Cara Z. Lowen	Reg. No. 38,227
William J. Daley, Jr.	Reg. No. 35,487
Christine C. O'Day	Reg. No. 38,256
Robert L. Buchanan	Reg. No. 40,927
David E. Tucker	Reg. No. 27,840
Lisa Swiszcz Hazzard	Reg. No. 44,368
John B. Alexander	Reg. No. 48,399
Steven M. Jensen	Reg. No. 42,693
Richard Roos	Reg. No.45,053

Send Correspondence to:

Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group
EDWARDS & ANGELL, LLP
P.O. Box 9169 Boston, Massachusetts 02209 USA

Direct Telephone Calls to:

Peter Corless	(617) 517-5557
Telephone:	(617) 439-4444
Facsimile:	(617) 439-4170

-00

Full name of sole or first inventor(s) Andre Rosowsky	
Sole or first inventor(s)'s signature Andre Rosowsky	Date: 12/14/01
Residence 76 Lindbergh Avenue, Needham, MA 02194 MA	
Citizenship USA	
Post Office Address	

BOS2_180620.1